At the 2024 Precision Health Summit, Amrie Grammer, Founder, President, and Chief Scientific Officer of AMPEL Biosolutions, presents a vision of how precision medicine can reshape autoimmune and inflammatory disease treatment.
Dr. Grammer is a Biotech Executive and NIH-trained Scientist-Entrepreneur (Immunology, Genomics, Pharmacology, ML/PredictiveAI) who has successfully translated her discoveries into a precision health business with prognostic tests for patients and monitoring biomarkers for pharma.
AMPEL’s ARPA-H spoke election highlights one-of-a-kind Precision Health tests that predict inflammation and abnormal drug targets from gene expression utilizing “explainable AI” (xAI). Other corporate Hub Spoke members include Verily, Datavant, Velsara, QuidelOrtho and Biolabs.
CBIC of Virginia honored the team with “Innovator-of-the-Year” last night June 1st for the AMPEL Genomic Platform of RNA analytics and Machine Learning for dynamic disease management through flare prediction & personalized decision support for drug options. Charlottesville Business Innovation Council (CBIC) presented AMPEL’s “Innovator-of-the-Year” award at the University of Virginia Research Park.
Virginia officials recognized AMPEL BioSolutions for their dedication to identifying, training, and retaining STEM-trained workers, especially in the area of precision medicine. The annual award recognizes Virginia employers who provide high-quality internships to students.
Tune in to this exciting episode of BioTalk with Rich Bendis, featuring Dr. Amrie Grammer, Co-Founder of AMPEL BioSolutions. In this enlightening discussion, Dr. Grammer unveils the secrets behind AMPEL’s remarkable success in precision medicine, making this episode a must-listen.